© 1991 by Oxford University Press
Journal of the National Cancer Institute, Vol. 83, No. 9, 613-620,
May 1, 1991
© 1991 Oxford University Press
Serotonin Antagonists: A New Class of Antiemetic Agents
Section of Medical Oncology, Evans Memorial Department of Clinical Research, and Department of Medicine, Boston University Medical Center Boston, Mass
Division of Hematology/Oncology, University of California, Davis, and Veterans Administration Medical Center Martinez, Calif
*Correspondenee to: Paul J. Hesketh, MD, Section of Medical Oncology, The University Hospital, 88 E Newton St, Boston, MA 02118
Despite a number of significant advances over the past decade, prevention and treatment of chemotherapy-induced emesis remain formidable problems, particularly with cisplatin-containing regimens. Nearly one third of patients receiving high-dose cisplatin still experience substantial emesis despite the best available conventional antiemetics, and the toxic effects of these agents remain quite troublesome. In recent years, a new class of agents, the serotonin antagonists, has been identified. These agents hold promise for clinical utility in a wide range of areas. Selective antagonists of the serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor have proven in early clinical trials to be potent antiemetic agents in patients receiving cytotoxic chemotherapy, with efficacy comparable to or superior to that of conventional antiemetics. Toxic effects to date with the 5-HT3 receptor antagonists have been modest. The current state of knowledge with respect to these agents as antiemetics for patients receiving cytotoxic chemotherapy is summarized. [J Natl Cancer Inst 83:613-620,1991]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Shah, T. DeGroot, and G. Apseloff Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J. Clin. Pharmacol., October 1, 2006; 46(10): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Ferreira Filho, A. Di Leo, M. Paesmans, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Awada, F. Cardoso, S. Dolci, et al. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions Ann. Onc., March 1, 2002; 13(3): 416 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hole, A. Conway, and S. Quadir Audit of efficacy of 3 mg versus 1 mg of intravenous granisetron as antiemetic prophylaxis against acute emesis caused by cisplatin or melphalan Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 194 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Hesketh, R. J. Gralla, R. T. Webb, W. Ueno, S. DelPrete, M. E. Bachinsky, N. L. Dirlam, C. B. Stack, and S. L. Silberman Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis J. Clin. Oncol., January 1, 1999; 17(1): 338 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grunberg and P. J. Hesketh Control of Chemotherapy-Induced Emesis N. Engl. J. Med., December 9, 1993; 329(24): 1790 - 1796. [Full Text]
|
|
|
|
|
|
M. Levitt, D. Warr, L. Yelle, H. L. Rayner, W. S. Lofters, D. J. Perrault, K. S. Wilson, J. Latreille, M. Potvin, E. Warner, et al. Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil N. Engl. J. Med., April 15, 1993; 328(15): 1081 - 1084. [Abstract] [Full Text]
|
|